HC Wainwright Cuts X4 Pharmaceuticals (NASDAQ:XFOR) Price Target to $1.50

X4 Pharmaceuticals (NASDAQ:XFOR) had its target price decreased by HC Wainwright from $5.00 to $1.50 in a report issued on Thursday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Separately, Stifel Nicolaus dropped their price objective on shares of X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Thursday.

X4 Pharmaceuticals Trading Down 1.6 %

NASDAQ XFOR opened at $0.40 on Thursday. The firm has a market capitalization of $67.99 million, a price-to-earnings ratio of -4.48 and a beta of 0.39. The company’s 50 day moving average price is $0.58 and its 200 day moving average price is $0.75. X4 Pharmaceuticals has a one year low of $0.26 and a one year high of $1.60. The company has a debt-to-equity ratio of 0.79, a quick ratio of 6.04 and a current ratio of 6.07.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its quarterly earnings data on Wednesday, August 14th. The company reported $0.01 earnings per share (EPS) for the quarter. The firm had revenue of $3.43 million for the quarter. On average, sell-side analysts predict that X4 Pharmaceuticals will post -0.65 EPS for the current year.

Insider Buying and Selling

In related news, CFO Adam S. Mostafa sold 230,645 shares of X4 Pharmaceuticals stock in a transaction on Monday, October 7th. The shares were sold at an average price of $0.55, for a total value of $126,854.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Paula Ragan sold 239,436 shares of X4 Pharmaceuticals stock in a transaction on Monday, October 7th. The stock was sold at an average price of $0.55, for a total transaction of $131,689.80. Following the completion of the sale, the chief executive officer now owns 1,057,713 shares of the company’s stock, valued at approximately $581,742.15. This trade represents a 18.46 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 580,800 shares of company stock worth $321,447. Insiders own 1.62% of the company’s stock.

Hedge Funds Weigh In On X4 Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in XFOR. Price T Rowe Associates Inc. MD boosted its holdings in X4 Pharmaceuticals by 46.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 39,307 shares of the company’s stock worth $55,000 after purchasing an additional 12,514 shares during the period. Bank of New York Mellon Corp boosted its holdings in X4 Pharmaceuticals by 39.7% in the second quarter. Bank of New York Mellon Corp now owns 469,372 shares of the company’s stock worth $272,000 after purchasing an additional 133,398 shares during the period. Rhumbline Advisers boosted its holdings in X4 Pharmaceuticals by 14.6% in the second quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock worth $109,000 after purchasing an additional 23,831 shares during the period. XTX Topco Ltd acquired a new position in X4 Pharmaceuticals in the second quarter worth $65,000. Finally, Ensign Peak Advisors Inc boosted its holdings in X4 Pharmaceuticals by 4.6% in the second quarter. Ensign Peak Advisors Inc now owns 2,546,458 shares of the company’s stock worth $1,477,000 after purchasing an additional 111,032 shares during the period. Institutional investors and hedge funds own 72.03% of the company’s stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.